does blue cross cover glp 1 for weight loss Why Blue Shield is rolling back coverage of GLP-1 drugs in Massachusetts How to Find a Health

CDSCO / Business Standard, March 2026 Phase III Trial Requirement DCGI requires Indian manufacturers to submit Phase III clinical trial data from Indian patients before approval not just bioequivalence data used for standard generics

At least one reviewer reported that their personal information was leaked and subsequently used by scammers

The messaging here is so wrong coming from an athlete like her and very dangerous for society, commented a third person

Prescribing trends mirrored this pattern: AOM semaglutide saw its largest monthly increase in July, stabilized from SeptemberNovember, then rose modestly in NovemberDecember and accelerated through February 2026

Insight: The Mounjaro Effect and Novo Nordisks Strategic Pivot Eli Lilly's dual-action drug, Mounjaro (tirzepatide, marketed as Zepbound for obesity), has been a phenomenal market disrupter

In recent years, many payers have taken steps to limit the costs of GLP-1s and introduced limits to coverage for the use of these products for weight loss